Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Opinion Editor's Corner ESC 2016

My Takeaways From ESC 2016: Eye-Rolling, Disappointments, and a Sobering Comeuppance

Shelley Wood

September 08, 2016

Presentation ESC 2016

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

Presenter: Raban V. Jeger

August 31, 2016

News Conference News ESC 2016

BASKET-SAVAGE: DES Reign for Saphenous Vein Graft PCI Amid Declining Use

Shelley Wood

August 31, 2016

News Conference News ESC 2016

NORSTENT: Do Modern-day Bare-Metal Stents Stand Up to Drug-Eluting Stents?

Shelley Wood

August 30, 2016

News Conference News ESC 2015

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Caitlin E. Cox

September 02, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2014

PROTECT: ZES Sustain Lead Over SES at 5 Years

Caitlin E. Cox

September 03, 2014

News Conference News ESC 2014

FAME 2: FFR-Guided PCI Continues on Same Trajectory from 1 to 2 Years

Caitlin E. Cox

September 02, 2014

News Conference News ESC 2014

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

Yael L. Maxwell

September 01, 2014

Presentation ESC 2014

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents

Presenter: Christoph Varenhorst

August 30, 2014

News Conference News ESC 2014

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

Todd Neale

August 30, 2014

News Conference News ESC 2013

Meta-analysis: Best Outcomes Seen with Newer-Generation DES in Women

Yael L. Maxwell

September 02, 2013

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

News Conference News ESC 2012

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Caitlin E. Cox

August 29, 2012

News Conference News ESC 2012

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

August 27, 2012

News Conference News

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

September 02, 2011

News Conference News

Landmark Analyses Show Downside of Prolonged Antiplatelet Therapy

September 02, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

News Conference News

New-Generation DES Reduce Restenosis, Stent Thrombosis

August 29, 2011

Advertisement

My Takeaways From ESC 2016: Eye-Rolling, Disappointments, and a Sobering Comeuppance

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

BASKET-SAVAGE: DES Reign for Saphenous Vein Graft PCI Amid Declining Use

NORSTENT: Do Modern-day Bare-Metal Stents Stand Up to Drug-Eluting Stents?

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

PROTECT: ZES Sustain Lead Over SES at 5 Years

FAME 2: FFR-Guided PCI Continues on Same Trajectory from 1 to 2 Years

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

Meta-analysis: Best Outcomes Seen with Newer-Generation DES in Women

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

Landmark Analyses Show Downside of Prolonged Antiplatelet Therapy

Long-term Antiplatelet Therapy: All Risk, No Benefit

New-Generation DES Reduce Restenosis, Stent Thrombosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content